[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593964":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":23,"interventions":35,"overallOfficials":13,"centralContacts":13,"locations":42,"responsibleParty":59,"collaborators":13,"id":61,"slug":13,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":13,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":13,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":13,"overallStatus":80,"whyStopped":13,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of subjects with glabellar line improvement* rate at maximum frown based on the investigator's on-site assessment at 4 weeks after IP administration","Improvement means FWS grade of \"0\" or \"1\" with a ≥2-point improvement from baseline","At 4 weeks after IP administration",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"DOUBLE",[21,22],"PARTICIPANT","INVESTIGATOR",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"DWP712 inj.","EXPERIMENTAL","The investigational product will be administered by a single intramuscular injection, and 4 U\u002F0.1 mL of the IP will be injected into a total of 5 sites, totaling 20 U\u002F0.5 mL.",[29],"Biological: DWP712 inj.",{"label":31,"type":32,"description":27,"interventionNames":33},"Botox® 100 Units","ACTIVE_COMPARATOR",[34],"Biological: Botox® 100 Units",[36,40],{"type":37,"name":25,"description":38,"armGroupLabels":39,"otherNames":13},"BIOLOGICAL","Clostridium botulinum Toxin",[25],{"type":37,"name":31,"description":38,"armGroupLabels":41,"otherNames":13},[31],[43],{"facility":44,"status":13,"city":45,"state":13,"zip":13,"country":46,"countryCode":13,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Chung-Ang University Hosptial","Seoul","South Korea",{"type":48,"coordinates":49},"Point",[50,51],126.9784,37.566,{"lat":51,"lon":50},[54],{"name":55,"role":56,"phone":57,"phoneExt":13,"email":58},"Beom Joon Kim, MD, phD","CONTACT","+82262991525","beomjoon74@gmail.com",{"type":60,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100593964",false,"NCT07013279","Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines","Inclusion Criteria:\n\n\\- Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening\n\nExclusion Criteria:\n\n\\- Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator",true,"ALL","19 Years","65 Years",{"count":72,"type":73},324,"ESTIMATED","INTERVENTIONAL",[76],"PHASE3","To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines",[79],"Glabellar Lines","NOT_YET_RECRUITING","2025-06-02",{"date":83,"type":84},"2025-06-10","ACTUAL",{"date":86,"type":73},"2025-07-15",{"date":88,"type":73},"2026-03-31",{"name":5,"class":6},1]